Reported about 8 hours ago
Travere Therapeutics, Inc. (NASDAQ:TVTX) reached an all-time high after the FDA canceled plans for an advisory committee related to its drug application for treating focal segmental glomerulosclerosis (FSGS). Following the news, shares jumped 26.2% to close at $27.31. The cancellation signals fewer concerns from the FDA regarding the drug candidate, Filspari, which aims to be the first approved therapy for FSGS, a significant cause of kidney failure. The company anticipates FDA approval by January 2026 and is preparing for the drug's commercial launch.
Source: YAHOO